Premium Nahrungsergänzungsmittel | artgerecht

D2C7 - Bispecific Antibody for Glioblastoma

D2C7 is a bispecific antibody under oncological investigation that simultaneously targets EGFRvIII and wild-type EGFR on tumor cells, activating the immune system against glioblastoma.

Regular tips about health Regular tips about health

Things worth knowing about "D2C7"

D2C7 is a bispecific antibody under oncological investigation that simultaneously targets EGFRvIII and wild-type EGFR on tumor cells, activating the immune system against glioblastoma.

What is D2C7?

D2C7 is a bispecific antibody currently being investigated in preclinical and clinical cancer research. It was specifically developed for the treatment of glioblastoma (GBM), one of the most aggressive primary brain tumors in humans. The antibody can simultaneously recognize two distinct targets on the surface of tumor cells: the mutated form of the epidermal growth factor receptor (EGFRvIII) and the wild-type EGFR (EGFRwt). This dual-targeting capability is a key feature that distinguishes D2C7 from other antibodies used in oncology.

Mechanism of Action

D2C7 belongs to the class of bispecific antibodies and works by binding two different antigens present on cancer cells. By targeting both EGFRvIII and EGFRwt, the antibody is able to recognize a broad spectrum of glioblastoma cells, since not all tumor cells carry the same mutation.

Bispecific Binding: D2C7 recognizes both the mutated variant (EGFRvIII) and the overexpressed normal form (EGFRwt) of the epidermal growth factor receptor on tumor cells.
Immune Cell Activation: When used as part of an immunotherapy approach or conjugated to a toxin, D2C7 can direct immune cells, particularly T-cells, toward tumor cells to initiate their destruction.
Broad Target Profile: Because glioblastomas often contain a heterogeneous cell population, antibodies targeting only a single marker may be less effective. D2C7 addresses this resistance mechanism by simultaneously covering both EGFR forms.

Clinical Use and Research Status

D2C7 is currently under clinical investigation. Phase I clinical trials in patients with recurrent glioblastoma are examining the safety, tolerability, and early signs of efficacy of the antibody. In these trials, D2C7 is frequently administered directly into or around the tumor using a technique known as convection-enhanced delivery (CED), which allows targeted drug delivery to the brain while minimizing systemic side effects.

Areas of Application

Recurrent glioblastoma (GBM)
EGFR-positive brain tumors
Patients who no longer respond to standard therapies

Side Effects and Safety

As D2C7 is still under clinical investigation, its complete side effect profile has not yet been fully established. Based on studies conducted so far, typical reactions associated with antibody-based therapies have been observed, including:

Local inflammatory reactions at the site of administration
Immune-mediated reactions
Neurological symptoms resulting from intracranial application

Safety profiles continue to be closely monitored in ongoing and planned clinical trials.

Significance for Oncology

Glioblastoma is considered one of the most challenging cancers in modern medicine, as it grows extremely aggressively and responds poorly to many standard therapies. D2C7 represents a promising approach to targeted immunotherapy tailored to the molecular characteristics of this tumor. If further studies confirm its efficacy and safety, D2C7 could represent a new therapeutic option for patients suffering from this difficult-to-treat brain tumor.

References

Chandramohan, V. et al. - Nat Med. 2017; D2C7-IT, a bispecific immunotoxin targeting EGFRvIII and EGFR for glioblastoma therapy - Nature Medicine, Vol. 23, pp. 1312–1320.
ClinicalTrials.gov - Study of D2C7-IT for Recurrent Malignant Glioma (NCT02303678) - U.S. National Library of Medicine.
Bhaskaran, V. et al. - Targeting EGFR in Glioblastoma: Challenges and Therapeutic Opportunities - Frontiers in Oncology, 2019.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.